tradingkey.logo

Paratek Pharmaceuticals To Acquire Optinose for Up To $330 Million

ReutersMar 20, 2025 1:29 AM

- Paratek Pharmaceuticals:

  • PARATEK PHARMACEUTICALS TO ACQUIRE OPTINOSE, CREATING SIGNIFICANT COMMERCIAL EXPANSION OPPORTUNITIES FOR XHANCE® IN CHRONIC RHINOSINUSITIS (CRS)

  • PARATEK PHARMACEUTICALS - TOTAL TRANSACTION VALUE OF UP TO $330 MILLION

  • PARATEK PHARMACEUTICALS- POTENTIAL CONSIDERATION OF UP TO $14 PER SHARE, INCLUDING UPFRONT CONSIDERATION OF $9 PER SHARE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI